Delving into the Latest Updates on Hangzhou Weiben Pharmaceutical Co. Ltd. with Synapse

Overview

Tags

Neoplasms

Hemic and Lymphatic Diseases

Immune System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Hemic and Lymphatic Diseases	2
Endocrinology and Metabolic Disease	1
Immune System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

c-Myc(Myc proto-oncogene protein)	1

主要目的：评估WBC100胶囊在复发或难治性急性髓系白血病患者中的安全性和耐受性；并探索剂量限制性毒性（DLT）和最大耐受剂量（MTD），为II期临床试验推荐给药剂量（RP2D）的确定提供依据。次要目的：评价WBC100胶囊在复发或难治性急性髓系白血病患者中的药代动力学（PK）特征；评估WBC100胶囊在复发或难治性急性髓系白血病患者中的初步疗效。

[Translation]

Primary objective: To evaluate the safety and tolerability of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia; and to explore the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) to provide a basis for determining the recommended dose (RP2D) for Phase II clinical trials. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia; to evaluate the preliminary efficacy of WBC100 capsules in patients with relapsed or refractory acute myeloid leukemia.

Start Date-

Sponsor / Collaborator

Hangzhou Weiben Pharmaceutical Co. Ltd.

CTR20211600 / RecruitingPhase 1

WBC100胶囊在C-Myc阳性实体瘤患者中的安全性、耐受性、药代动力学特征以及初步疗效的开放、剂量递增的I期临床研究

[Translation] An open-label, dose-escalation phase I clinical study of the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of WBC100 capsules in patients with C-Myc-positive solid tumors

主要目的：评估WBC100胶囊在C-Myc阳性晚期实体瘤患者中的安全性和耐受性；确定WBC100胶囊在C-Myc阳性晚期实体瘤患者中的剂量限制性毒性（DLT）和最大耐受剂量（MTD）。次要目的：评价WBC100胶囊在C-Myc阳性晚期实体瘤患者中的药代和药效动力学特征；按照实体瘤疗效评价标准（RECIST v1.1），评估WBC100胶囊在C-Myc阳性胰腺癌患者中的初步抗肿瘤活性；探索II期推荐剂量（RP2D）。

[Translation]

Primary objectives: To evaluate the safety and tolerability of WBC100 capsules in patients with C-Myc-positive advanced solid tumors; To determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of WBC100 capsules in patients with C-Myc-positive advanced solid tumors. Secondary objectives: To evaluate the pharmacokinetic and pharmacodynamic characteristics of WBC100 capsules in patients with C-Myc-positive advanced solid tumors; According to the solid tumor efficacy evaluation criteria (RECIST v1.1), to evaluate the preliminary anti-tumor activity of WBC100 capsules in patients with C-Myc-positive pancreatic cancer; To explore the recommended dose (RP2D) for Phase II.

Start Date17 Dec 2021

Sponsor / Collaborator

Hangzhou Weiben Pharmaceutical Co. Ltd.

100 Clinical Results associated with Hangzhou Weiben Pharmaceutical Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Hangzhou Weiben Pharmaceutical Co. Ltd.

Login to view more data

100 Deals associated with Hangzhou Weiben Pharmaceutical Co. Ltd.

Login to view more data

100 Translational Medicine associated with Hangzhou Weiben Pharmaceutical Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

1

Phase 1 Clinical

Login to view more data